Literature DB >> 27188284

Polyglutamine androgen receptor-mediated neuromuscular disease.

Elisa Giorgetti1, Andrew P Lieberman2.   

Abstract

An expanded polyglutamine (polyQ) tract at the amino-terminus of the androgen receptor (AR) confers toxic properties responsible for neuronal and non-neuronal degeneration in spinal and bulbar muscular atrophy (SBMA), one of nine polyQ expansion diseases. Both lower motor neurons and peripheral tissues, including skeletal muscle, are affected, supporting the notion that SBMA is not a pure motor neuron disease but a degenerative disorder of the neuromuscular system. Here, we review experimental evidence demonstrating both nerve and muscle degeneration in SBMA model systems and patients. We propose that polyQ AR toxicity targets these components in a time-dependent fashion, with muscle pathology predominating early and motor neuron loss becoming more significant at late stages. This model of pathogenesis has important therapeutic implications, suggesting that symptoms arising from degeneration of nerve or muscle predominate at different points and that directed interventions targeting these components will be variably effective depending upon disease progression.

Entities:  

Keywords:  Androgen receptor; CAG/polyglutamine disorder; Motor neuron; Skeletal muscle; Spinal and bulbar muscular atrophy

Mesh:

Substances:

Year:  2016        PMID: 27188284      PMCID: PMC5045769          DOI: 10.1007/s00018-016-2275-1

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  87 in total

Review 1.  The hinge region in androgen receptor control.

Authors:  Liesbeth Clinckemalie; Dirk Vanderschueren; Steven Boonen; Frank Claessens
Journal:  Mol Cell Endocrinol       Date:  2012-03-02       Impact factor: 4.102

Review 2.  Regulation of signaling protein function and trafficking by the hsp90/hsp70-based chaperone machinery.

Authors:  William B Pratt; David O Toft
Journal:  Exp Biol Med (Maywood)       Date:  2003-02

3.  17-AAG, an Hsp90 inhibitor, ameliorates polyglutamine-mediated motor neuron degeneration.

Authors:  Masahiro Waza; Hiroaki Adachi; Masahisa Katsuno; Makoto Minamiyama; Chen Sang; Fumiaki Tanaka; Akira Inukai; Manabu Doyu; Gen Sobue
Journal:  Nat Med       Date:  2005-09-11       Impact factor: 53.440

4.  Progressive proximal spinal and bulbar muscular atrophy of late onset. A sex-linked recessive trait.

Authors:  W R Kennedy; M Alter; J H Sung
Journal:  Neurology       Date:  1968-07       Impact factor: 9.910

5.  Widespread nuclear and cytoplasmic accumulation of mutant androgen receptor in SBMA patients.

Authors:  Hiroaki Adachi; Masahisa Katsuno; Makoto Minamiyama; Masahiro Waza; Chen Sang; Yuji Nakagomi; Yasushi Kobayashi; Fumiaki Tanaka; Manabu Doyu; Akira Inukai; Mari Yoshida; Yoshio Hashizume; Gen Sobue
Journal:  Brain       Date:  2005-01-19       Impact factor: 13.501

Review 6.  Targeting Hsp90/Hsp70-based protein quality control for treatment of adult onset neurodegenerative diseases.

Authors:  William B Pratt; Jason E Gestwicki; Yoichi Osawa; Andrew P Lieberman
Journal:  Annu Rev Pharmacol Toxicol       Date:  2014-09-25       Impact factor: 13.820

7.  Small ubiquitin-like modifier (SUMO) modification of the androgen receptor attenuates polyglutamine-mediated aggregation.

Authors:  Sarmistha Mukherjee; Monzy Thomas; Nahid Dadgar; Andrew P Lieberman; Jorge A Iñiguez-Lluhí
Journal:  J Biol Chem       Date:  2009-06-04       Impact factor: 5.157

8.  Muscle expression of mutant androgen receptor accounts for systemic and motor neuron disease phenotypes in spinal and bulbar muscular atrophy.

Authors:  Constanza J Cortes; Shuo-Chien Ling; Ling T Guo; Gene Hung; Taiji Tsunemi; Linda Ly; Seiya Tokunaga; Edith Lopez; Bryce L Sopher; C Frank Bennett; G Diane Shelton; Don W Cleveland; Albert R La Spada
Journal:  Neuron       Date:  2014-04-16       Impact factor: 17.173

9.  Activation of Hsp70 reduces neurotoxicity by promoting polyglutamine protein degradation.

Authors:  Adrienne M Wang; Yoshinari Miyata; Susan Klinedinst; Hwei-Ming Peng; Jason P Chua; Tomoko Komiyama; Xiaokai Li; Yoshihiro Morishima; Diane E Merry; William B Pratt; Yoichi Osawa; Catherine A Collins; Jason E Gestwicki; Andrew P Lieberman
Journal:  Nat Chem Biol       Date:  2012-12-09       Impact factor: 15.040

10.  Insulinlike growth factor (IGF)-1 administration ameliorates disease manifestations in a mouse model of spinal and bulbar muscular atrophy.

Authors:  Carlo Rinaldi; Laura C Bott; Ke-lian Chen; George G Harmison; Masahisa Katsuno; Gen Sobue; Maria Pennuto; Kenneth H Fischbeck
Journal:  Mol Med       Date:  2012-12-06       Impact factor: 6.354

View more
  11 in total

Review 1.  Genetic approaches to the treatment of inherited neuromuscular diseases.

Authors:  Bhavya Ravi; Anthony Antonellis; Charlotte J Sumner; Andrew P Lieberman
Journal:  Hum Mol Genet       Date:  2019-10-01       Impact factor: 6.150

2.  Role of Mutant TBP in Regulation of Myogenesis on Muscle Satellite Cells.

Authors:  Dong-Ming Zhao; Sui-Qiang Zhu; Fu-Rong Wang; Shan-Shan Huang
Journal:  Curr Med Sci       Date:  2019-10-14

3.  Correlation of insulin resistance and motor function in spinal and bulbar muscular atrophy.

Authors:  Hideaki Nakatsuji; Amane Araki; Atsushi Hashizume; Yasuhiro Hijikata; Shinichiro Yamada; Tomonori Inagaki; Keisuke Suzuki; Haruhiko Banno; Noriaki Suga; Yohei Okada; Manabu Ohyama; Tohru Nakagawa; Ken Kishida; Tohru Funahashi; Iichiro Shimomura; Hideyuki Okano; Masahisa Katsuno; Gen Sobue
Journal:  J Neurol       Date:  2017-02-22       Impact factor: 4.849

4.  Androgen receptor polyglutamine expansion drives age-dependent quality control defects and muscle dysfunction.

Authors:  Samir R Nath; Zhigang Yu; Theresa A Gipson; Gregory B Marsh; Eriko Yoshidome; Diane M Robins; Sokol V Todi; David E Housman; Andrew P Lieberman
Journal:  J Clin Invest       Date:  2018-07-23       Impact factor: 14.808

5.  Deubiquitinase USP7 contributes to the pathogenicity of spinal and bulbar muscular atrophy.

Authors:  Anna Pluciennik; Yuhong Liu; Elana Molotsky; Gregory B Marsh; Bedri Ranxhi; Frederick J Arnold; Sophie St-Cyr; Beverly Davidson; Naemeh Pourshafie; Andrew P Lieberman; Wei Gu; Sokol V Todi; Diane E Merry
Journal:  J Clin Invest       Date:  2021-01-04       Impact factor: 14.808

Review 6.  Polyglutamine Repeats in Neurodegenerative Diseases.

Authors:  Andrew P Lieberman; Vikram G Shakkottai; Roger L Albin
Journal:  Annu Rev Pathol       Date:  2018-08-08       Impact factor: 23.472

7.  Network analysis reveals crosstalk between autophagy genes and disease genes.

Authors:  Ji-Ye Wang; Wei-Xuan Yao; Yun Wang; Yi-Lei Fan; Jian-Bing Wu
Journal:  Sci Rep       Date:  2017-03-15       Impact factor: 4.379

Review 8.  Intrinsic Disorder in Proteins with Pathogenic Repeat Expansions.

Authors:  April L Darling; Vladimir N Uversky
Journal:  Molecules       Date:  2017-11-24       Impact factor: 4.411

9.  DNA methylation inhibitor attenuates polyglutamine-induced neurodegeneration by regulating Hes5.

Authors:  Naohide Kondo; Genki Tohnai; Kentaro Sahashi; Madoka Iida; Mayumi Kataoka; Hideaki Nakatsuji; Yutaka Tsutsumi; Atsushi Hashizume; Hiroaki Adachi; Haruki Koike; Keiko Shinjo; Yutaka Kondo; Gen Sobue; Masahisa Katsuno
Journal:  EMBO Mol Med       Date:  2019-05       Impact factor: 12.137

10.  Systemic Delivery of MicroRNA Using Recombinant Adeno-associated Virus Serotype 9 to Treat Neuromuscular Diseases in Rodents.

Authors:  Naemeh Pourshafie; Philip R Lee; Ke-Lian Chen; George G Harmison; Laura C Bott; Kenneth H Fischbeck; Carlo Rinaldi
Journal:  J Vis Exp       Date:  2018-08-10       Impact factor: 1.355

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.